Core Insights - Myriad Genetics announced new clinical data from the MONSTAR-SCREEN-3 study, demonstrating the effectiveness of its ultra-sensitive Precise™ MRD Test in detecting circulating tumor DNA (ctDNA) across various cancer types [1][2] - The study achieved 100% baseline detection of ctDNA and found that 60% of patients testing positive one month post-surgery had ctDNA levels only detectable via the ultra-sensitive test [2] Study Findings - The MONSTAR-SCREEN-3 study involved approximately 1,200 patients across more than 20 cancer types, focusing on the application of MRD monitoring using Precise MRD [3] - The study aims to provide high-quality clinical evidence for the broad application of MRD testing, particularly in low-shedding tumors [3] - ctDNA levels are assessed at multiple time points, including diagnosis, post-neoadjuvant therapy, and post-surgery, with follow-ups every 3-6 months for at least two years [3] Test Details - Myriad's Precise MRD test is a tumor-informed, whole-genome sequencing (WGS)-based test that monitors hundreds to thousands of tumor-specific variants, offering exceptional sensitivity in ctDNA detection [4][5] - The test can detect tumor fractions as low as 0.0001% (1 part per million) and has shown a clinically meaningful lead time in detecting recurrence compared to imaging [5] Clinical Implications - The results indicate that ctDNA status after neoadjuvant treatment is strongly associated with pathological response, highlighting the potential for personalized treatment strategies [2][5] - The enhanced sensitivity of the Precise MRD test allows for better monitoring and treatment planning for patients with low-shedding tumors, such as breast and renal cancers [2][4]

Core Insights - Aeries Technology, Inc. has announced a strategic partnership with Fortra to establish Global Capability Centers (GCCs) in India and Mexico, aimed at expanding Fortra's workforce and creating a nearshore hub [1][2] - The collaboration will leverage Aeries' expertise to enhance Fortra's core business functions, providing access to a skilled talent pool, ensuring cost efficiency, and supporting operational scaling [2][3] - This partnership is expected to foster innovation, optimize operational efficiency, and accelerate digital transformation initiatives for Fortra [2] Company Overview - Aeries Technology is a global leader in GCC solutions, focusing on establishing GCCs for Private Equity's Portfolio Companies and offering a comprehensive suite of Advisory & Value Creation solutions [5] - The company has grown to over 1,800 professionals since its founding in 2012 and has received the Great Place to Work Certification for two consecutive years, highlighting its commitment to workforce development [6] - Fortra specializes in advanced cybersecurity solutions, providing comprehensive protection across the cyber kill chain, with capabilities for real-time threat intelligence and flexible solution delivery [4]

On June 2, 2025, AB Akola Group's CFO, Mažvydas Šileika, shared a slide presentation with the investment community during the Nasdaq Vilnius Stock Exchange’s traditional event, “CEO Meets Investors”. Attached: presentation demonstrated during the event. For more information: CFO of AB Akola Group Mažvydas ŠileikaMob. +370 619 19 403E-mail m.sileika@akolagroup.lt Attachment Nasdaq Susitikimas su vadovais ...

Retail turnover (including VAT) of Apranga Group amounted to EUR 30.1 million in May 2025 and decreased by 7.0% compared to May 2024. The decline in retail turnover of Apranga Group in May 2025 was influenced by weaker-than-usual sales of the spring-summer season collections, due to unusually low average air temperatures. In January through May 2025, the retail turnover of Apranga Group (including VAT) totalled EUR 132.1 million and increased by 0.3% year-to-year. In January-May 2025, the retail turnover of ...

BOCA RATON, FL, June 02, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced an LOI with Kamino Finance, the largest Solana DeFi lending protocol with more than $4B in deposited assets. As part of the collaboration, Kamino intends to integrate dfdvSOL, an LST built by Sanctum, into its suite of capital-efficient DeFi products. The partnership w ...

International recognition of cutting-edge ASUS design, innovation, and craftsmanship across five diverse product categories TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- ASUS today announced that it has been honored with 41 Red Dot Design Awards for Product Design 2025, reinforcing the company's long-standing reputation for pushing the boundaries of innovation and excellence in product design. These wins highlight the ASUS commitment to creating technology that excels in both form and function, in line with it ...

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND, OTCQX: TSNDF), a leading North American cannabis company, today announced that Keith Stauffer, Chief Financial Officer, will be departing the Company on July 18, 2025, to pursue a career opportunity outside of the cannabis industry. Mr. Stauffer will remain in his role through the transition period to ensure a smooth handover. Effective upon his departure, Alisa Campbell, currently Senior Vice President, ...

Core Insights - Actuate Therapeutics announced positive topline results from the Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma, indicating a significant improvement in overall survival [1][2][5] Study Results - The study achieved its primary endpoint with a median overall survival of 10.1 months for the elraglusib/GnP group compared to 7.2 months for the GnP group, resulting in a 37% reduction in the risk of death (HR = 0.63) [2][8] - The 12-month survival rate was 44.1% in the elraglusib/GnP arm versus 22.3% in the GnP arm, demonstrating a doubling of survival rates [2][8] - Continued survival benefits were observed at 18 and 24 months, with survival rates of 19.7% vs 4.4% and 13.8% vs 0% for elraglusib/GnP compared to GnP alone, respectively [8] - The overall response rate was numerically improved at 29.0% for the elraglusib/GnP arm compared to 21.8% for the GnP arm [8] Safety Profile - The trial met its primary safety endpoint, with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in the elraglusib/GnP arm being similar to those in the GnP arm, indicating a favorable risk-benefit profile [8] - Most treatment-related adverse events (TRAEs) were Grade 1-2, with transient visual impairments being the most common [8] Mechanism of Action - Elraglusib works by inhibiting GSK-3β, which may enhance chemotherapy activity, activate anti-tumor immunity, and regulate gene expression, potentially leading to improved survival outcomes [10][11] Clinical Context - The KOL event highlighted the unmet need in mPDAC and the potential of elraglusib to reshape treatment paradigms, emphasizing the importance of new drugs with unique mechanisms [4][5]

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”) is pleased to announce the appointment of Cameron MacKay as Vice President of Exploration effective June 01, 2025. Mr. MacKay is a seasoned uranium exploration executive with over a decade of experience and a track record of uranium discovery in the Athabasca Basin. “We are extremely pleased to welcome Cameron to Foremost's leadership team," said Jason Barnard, Pr ...

On 5 May 2025, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 20 of 2 May 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 120 million during the period 5 May to 31 December 2025. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules). Tr ...